Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.
In April, a Securities and Exchange Commission filing revealed that Wojcicki planned to take the company private. 23andMe’s stock price had fallen below $1 per share at the time, down from its $10 ...
Diagnostic errors were involved in about one out of three adverse patient safety events analyzed in a new report from ECRI and the Institute for Safe Medication Practices PSO. Among the diagnostic ...